Pioglitazone, a synthetic ligand for PPARγ, induces apoptosis in RB-deficient human colorectal cancer cells

Apoptosis

Volumn 11, Issue 3, 2006, Pages 401-411

  Lee, C J ^a   Han, J S ^a   Seo, C Y ^a   Park, T H ^a   Kwon, H C ^a   Jeong, J S ^a   Kim, I H ^b   Yun, J ^a   Bae, Y S ^a   Kwak, J Y ^a   Park, J I ^a  

^a Dong A University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Apoptosis; PPAR ; RB deficient human colorectal cancer; XIAP

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL STRAIN SNU C2A; CELL STRAIN SNU C4; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYTOCHROMES C; ENZYME ACTIVATION; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; POLY(ADP-RIBOSE) POLYMERASES; PPAR GAMMA; RETINOBLASTOMA PROTEIN; THIAZOLIDINEDIONES;

EID: 33646387693     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-4003-z     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Water J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2000; 84: 1-7.
3. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-839.
4. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996; 12: 335-363.
5. Spiegelman BM, Flier JS. Adipogenesis and obesity: Rounding out the big picture. Cell 1996; 87: 377-389.
6. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Patridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998; 4: 1046-1052.
7. Forman BM, Tontonez P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta-12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-812.
8. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisley GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318-4323.
9. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-1055.
10. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome prolifertor-activated receptor induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75-80.
11. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237-241.
12. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
13. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-8811.
14. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998; 1: 465-470.
15. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-139.
16. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-1138.
17. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonist through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-405.
18. Kip in human pancreatic carcinoma cells. Cancer Res 2000; 60: 5558-5564.
19. WAF/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 1999; 261: 833-837.
20. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-gamma: From apoptosis to carcinogenesis. J Mol Endocrinol 2001; 27:1-9.
21. Min/+ mice. Nat Med 1998; 4: 1053-1057.
22. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998; 4: 1058-1061.
23. Gao CF, Ren S, Zhang L, Nakajima T, Ichinose S, Hara T, Koike K, Tsuchida N. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exp Cell Res 2001; 265: 145-151.
24. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, -gamma in the adult rat. Endocrinology 1996; 137: 354-366.
25. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281-299.
26. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917.
27. Li H, Heller DS, Leevy CB, Zierer KG, Klein KM. Troglitazone-induced fulminant hepatitis: Report of a case with autopsy findings. J Diabetes Complications 2000; 14: 175-177.
28. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998; 21: 2140-2143.
29. Kip1-associated cell cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 2003; 37: 1086-1096.
30. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704-711.
31. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-γ: From adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27: 1-9.
32. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-6218.
33. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARγ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 2003; 22: 4186-4193.
34. Brown TL, Patil S, Cianci CD, Morrow JS, Howe PH. Transforming growth factor β induces caspase 3-independent cleavage of II-spectrin (α-fodrin) coincident with apoptosis. J Biol Chem 1999; 274: 23256-23262.
35. Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of NF-κB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol 1999; 163: 590-598.
36. Mohr S, McCormick TS, Lapetina EG. Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: Dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059. Proc Natl Acad Sci USA 1998; 95: 5045-5050.
37. Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages require constitutive NF-κB activation to maintain A1 expression and mitochondrial homeostasis. Mol Cell Biol 2000; 20: 8855-8865.
38. Perfettini JL, Reed JC, Israel N, Martinou JC, Dautry-Varsat A, Ojcius DM. Role of Bcl-2 family members in caspase-independent apoptosis during Chlamydia infection. Infect Immun 2002; 70: 55-61.
39. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M. PIC-1/SUMO-1-modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999; 19: 5170-5178.
40. Untergasser G, Rumpold H, Plas E, Madersbacher S, Berger P. A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase-3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio. FASEB J 2001; 15: 673-683.
41. Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, Inoue H. Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ. Br J Cancer 2002; 86: 1303-1309.
42. 2 regulates apoptosis induction and nuclear factor-κB activation via a peroxisome proliferator-activated receptor-γ-independent mechanism in hepatocellular carcinoma. Lab Invest 2003; 83: 1529-1539.
43. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
44. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T , Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17: 2215-2223.
45. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
46. Herschman HR. Prostaglandin synthase 2. Biochem Biophys Acta 1996; 1299: 125-140.
47. Eberhart CE, Coffey RJ, Radhika A. Up-regulation of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187: 295-301.
48. Ristimaki A, Honkonen N, Jankala H. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1998; 58: 2929-2934.
49. Mahammed SI, Knapp DW, Boostwick DG. Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Res 1999; 59: 5647-5650.
50. Yang LW, Frucht H. Activation of the PPARγ pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001; 22: 1379-1383.